Disrupting a Convergent Acetylation Circuit Collapses Leukemic Identity Across AML Subtypes
Anagha Deshpande, Cho-Ying Chiang, Marlenne Perales, Neha Niranjan, Neelam Sinha, Darren Finlay, Alexandra Stevens, Emily Zahn, Benjamin A. Garcia, Irmela Jeremias, Mark Wunderlich, Kristen Jensen-Pergakes, Akshata Udyavar, Amy Carr, Andrew R. Nager, , Aniruddha J. Deshpande
This paper identifies an acetylation-dependent circuit controlling SEC integrity in AML, showing that disrupting KAT2A/B leads to broad anti-leukemic effects across subtypes.
bioRxiv · Jul 14, 2026 · PreprintCancer Biology